Sparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 10, 1999, Pages 2493-2496

  Kenny, George E ^a   Young, Patrick A ^a   Cartwright, Frank D ^a   Sjöström, Karen E ^a   Huang, Wai M ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; OFLOXACIN; SPARFLOXACIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; DRUG TARGETING; GENE MUTATION; MYCOPLASMA HOMINIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0032844996     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.10.2493     Document Type: Article

References (21)

1. Bébéar, C. M., A. Charron, J. M. Bové, C. Bébéar, and J. Renaudin. 1998. Cloning and nucleotide sequence of the topoisomerase IV parC and parE genes of Mycoplasma hominis. Antimicrob. Agents Chemother. 42:2024-2031.
2. Bébéar, C. M., H. Renaudin, A. Charron, J. M. Bové, C. Bébéar, and J. Renaudin. 1998. Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro. Antimicrob. Agents Chemother. 42:2304-2311.
3. Bébéar, C. M., J. M. Bové, C. Bébéar, and J. Renaudin. 1997. Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones. Antimicrob. Agents Chemother. 41:269-273.
4. Drlica, K., and X. Zhao. 1997. DNA Gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
5. Dybvig, K., and L. L. Voelker. 1996. Molecular biology of mycoplasmas. Annu. Rev. Microbiol. 50:25-57.
6. Edward, D. G. ff. 1955. A suggested classification and nomenclature for organisms in the pleuropneumonia group. Int. Bull. Bacteriol. Nomencl. Taxon. 5:85-93.
7. Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558.
8. Gootz, T. D., and K. E. Brighty. 1998. Chemistry and mechanism of action of the quinolone antibacterials, p. 29-80. In V. Andriole (ed.), The quinolones. Academic Press, Inc., New York, N.Y.
9. Hooper, D. C. 1998. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. Clin. Infect. Dis. 27(Suppl.):S54-S63.
10. Huang, W. M. 1996. Bacterial diversity based on type II DNA topoisomerase genes. Annu. Rev. Genet. 30:79-107.
11. Kato, J., Y. Nishimura, R. Imamura, H. Niki, S. Hiraga, and H. Suzuki. 1990. New topoisomerase essential for chromosome segregation in E. coli. Cell 63:393-404.
12. Kenny, G. E. 1991. Mycoplasmas, p. 478-482, 1263-1264, 1280. In A. Balows, W. J. Hausler, Jr., K. L. Herrman, H. D. Isenberg, and H. J. Shadomy (ed.), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C.
13. Kenny, G. E., and F. D. Cartwright. 1993. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116. Antimicrob. Agents Chemother. 37:1726-1727.
14. Kenny, G. E., P. A. Young, F. D. Cartwright, K. E. Sjöström, and W. M. Huang. 1998. Ofloxacin selects first-step parC mutations in Mycoplasma hominis whereas sparfloxacin selects for first-step gyrA mutations, p. 182. In Abstracts of the 6th International Symposium on New Quinolones.
15. Kenny, G. E., T. H. Hoolon, M. C. Roberts, F. D. Cartwright, and J. Hoyt. 1989. Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method. Antimicrob. Agents Chemother. 33:103-107.
16. Pan, X.-S., and L. M. Fisher. 1997. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41:471-474.
17. Pan, X.-S., and L. M. Fisher. 1998. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2810-2816.
18. Saiki, R. K. 1990. Amplification of genomic DNA, p. 13-20. In M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White (ed.), PCR protocols. Academic Press, Inc., New York, N.Y.
19. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
20. Tankovic, J., B. Perichon, J. Duval, and P. Courvalin. 1996. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40:2505-2510.
21. Zhao, X., C. Xu, J. Domagala, and K. Drlica. 1997. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. USA 94:13991-13996.